Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O95926
UPID:
SYF2_HUMAN
Alternative names:
CCNDBP1-interactor; p29
Alternative UPACC:
O95926; Q5TH73
Background:
Pre-mRNA-splicing factor SYF2, also known as CCNDBP1-interactor or p29, plays a crucial role in pre-mRNA splicing as a component of the spliceosome. This protein's involvement in the complex process of spliceosome assembly and pre-mRNA splicing highlights its importance in the regulation of gene expression.
Therapeutic significance:
Understanding the role of Pre-mRNA-splicing factor SYF2 could open doors to potential therapeutic strategies. Its critical function in gene expression regulation makes it a compelling target for research aimed at uncovering novel treatments.